Ob/Gyn Medical News about Breast Cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/NEU amplification as a predictive factor for efficacy
Journal of Korean Medical Science, 10/05/09

Han HS et al. – The combination of weekly paclitaxel plus trastuzumab as first-line chemotherapy is an effective regimen in patients with HER2-FISH-positive MBC. Furthermore, the magnitude of HER2 amplification is an independent predictive factor of TTP

Methods

54 patients with HER2-overexpressing MBC that were treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy from February 2004 to December 2006
Median follow-up of 28 months, median time to progression (TTP) 16.6 months and median overall survival 25.6 months
Therapy generally well tolerated, although 3 patients experienced reversible, symptomatic heart failure

Results

Of the 27 patients evaluable for the HER2 FISH, patients with HER2/CEP17 ratio of ≤ 4.0 had significantly shorter TTP than those with a HER2/CEP17 ratio of > 4.0
HER2/CEP17 ratio of > 4.0 identified as significant predictive factor of TTP by multivariate analysis

<< Previous
The effect of anti-eppin antibodies on ionophore A23187-induced...

Next >>
Human Papillomavirus Vaccine Uptake, Predictors of Vaccination,...